Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Multiple Myeloma × letermovir × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Hematologic Neoplasms 3 Primary Myelofibrosis 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Myeloproliferative Disorders 2 Myelodysplastic Syndromes 2 Lymphoma, Non-Hodgkin 2 Leukemia, Myeloid, Chronic-Phase 2 Leukemia, Myeloid, Acute 2 Leukemia, Myeloid, Accelerated Phase 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Hodgkin Disease 2 Multiple Myeloma 1 Cytomegalovirus Infections 1

Interventions

Dexamethasone 221 Lenalidomide 138 daratumumab 118 Bortezomib 89 pomalidomide 79 Calcium Dobesilate 71 carfilzomib 68 Cyclophosphamide 65 Specimen Handling 37 Biopsy 37 belantamab mafodotin 36 fludarabine 33 isatuximab 31 Magnetic Resonance Spectroscopy 31 dexamethasone acetate 29 dexamethasone 21-phosphate 29 auricularum 28 Melphalan 28 talquetamab 27 ixazomib 24 iberdomide 22 elotuzumab 19 selinexor 17 fludarabine phosphate 16 Whole-Body Irradiation 12 X-Rays 11 Stem Cell Transplantation 11 tocilizumab 10 Standard of Care 10 venetoclax 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06920251 2025-12-03

OPTIMUS-EL

Seoul National University Hospital

Phase 2 Recruiting

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡